MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX

MYX - MAYNE PHARMA GROUP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -4.14
Index: ASX300 | ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$7.24

12 Mar
2025

0.010

OPEN

$7.23

0.14%

HIGH

$7.25

928,548

LOW

$7.23

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-218.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx388.4 M
Book Value Per Share xxxxxxxxxxxxxxx559.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-9.6 M
Net Profit Margin xxxxxxxxxxxxxxx-43.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-30.98 %
Return on Invested Capital xxxxxxxxxxxxxxx-29.16 %
Return on Assets xxxxxxxxxxxxxxx-14.10 %
Return on Equity xxxxxxxxxxxxxxx-30.98 %
Return on Total Capital xxxxxxxxxxxxxxx-13.25 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx4 M
Long Term Debt xxxxxxxxxxxxxxx35 M
Total Debt xxxxxxxxxxxxxxx39 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx152 M
Price To Book Value xxxxxxxxxxxxxxx0.84

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx20.9 M
Capex % of Sales xxxxxxxxxxxxxxx5.37 %
Cost of Goods Sold xxxxxxxxxxxxxxx229 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx237 M
Research & Development xxxxxxxxxxxxxxx20 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxx xxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

04/03/2025

3

Hold

$7.40

2.21%

Canaccord Pharma notes Mayne Pharma's 1H25 result was strong and in line with the company's trading update. The main beat came from the women's health segment and strong margin performance in dermatology products.

The key focus now is on the bid from Cosette pharma which the broker expects to go through.

Target price of $7.4 (matching the bid price) and Hold rating are unchanged.
Access Extra Coverage Research History >

MYX STOCK CHART

FNArena News on MYX

1
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-03-25

Mar 07 2025 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Mar 05, 2025

Mar 05 2025 - Daily Market Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 28-02-25

Feb 28 2025 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Feb 27, 2025

Feb 27 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Feb 12, 2025

Feb 12 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps